• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    thieno derivatives [3,2- d] pyrimidines for the treatment of viral infections. the present invention relates to thieno [3,2-d] pyrimidine derivatives, processes for their preparation, pharmaceutical compositions, and their use in the treatment of viral infections.
    公开号:BR112016001570B1
    申请号:R112016001570-3
    申请日:2014-07-29
    公开日:2020-12-15
    发明作者:David Craig Mc Gowan；Pierre Jean-Marie Bernard Raboisson
    申请人:Janssen Sciences Ireland Uc；
    IPC主号:
    专利说明:

    [001] The present invention relates to thieno [3,2- d] pyrimidine derivatives, processes for their preparation, pharmaceutical compositions and their use in the treatment of viral infections.
    [002] The present invention relates to the use of derivatives of tieno [3,2-d] pyrimidine in the treatment of viral infections, immunological or inflammatory disorders, in which the modulation, or agonism, of receptors of the type Toll (TLRs) is involved. Toll-like receptors are primary transmembrane proteins characterized by an extracellular domain rich in leucine and a cytoplasmic extension that contains a conserved region. The innate immune system is able to recognize molecular patterns associated with pathogens through these TLRs expressed on the cell surface of certain types of immune cells. The recognition of foreign pathogens activates the production of cytokines and an increase in the expression of co-stimulating molecules in phagocytes. This leads to the modulation of the behavior of T lymphocytes.
    [003] It has been estimated that most mammal species have between ten and fifteen types of Toll-like receptors. Thirteen TLRs (called TLR1 to TLR13) have been identified in humans and mice together, and equivalent forms of many of these have been found in other mammalian species. However, equivalents of certain TLRs found in humans are not present in all mammals. For example, a gene that encodes a protein analogous to TLR10 in humans is present in mice, but appears to have been damaged at some point in the past by a retrovirus. On the other hand, mice express TLRs 11, 12 and 13, none of which are represented in humans. Other mammals can express TLRs that are not found in humans. Other non-mammalian species may have TLRs other than mammals, as demonstrated by TLR14, which is found in the Takifugu puffer fish. This can complicate the process of using experimental animals as models of human innate immunity.
    [004] For revisions on TLRs see the following review articles. Hoffmann, J.A., Nature, 426, pp. 33-38, 2003; Akira, S., Takeda, K., and Kaisho, T., Annual Rev. Immunology, 21, pp. 335-376, 2003; Ulevitch, R. J., Nature Reviews: Immunology, 4, pp. 512-520, 2004.
    [005] Compounds that indicate activity at Toll-like receptors have been previously described such as purine derivatives in WO 2006/117670, adenine derivatives in WO 98/01448 and WO 99/28321, and pyrimidines in WO 2009/067081.
    [006] However, there is a great need for new Toll-type receiver modulators that have preferential selectivity, greater power and an improved safety profile compared to prior art compounds.
    [007] According to the present invention there is provided a compound of formula (I)
    or a pharmaceutically acceptable salt, tautomer (s), stereoisomeric form, solvate or polymorph thereof, where R1 is selected from hydrogen, halogen, -CH3 or -CF3, R2 is selected from hydrogen, halogen, C1-6 alkyl or C3 cycloalkyl -6, R3 is C1-8 alkyl optionally substituted with one or more substituents selected independently from aryl, aryloxy, halogen, hydroxyl, alkylamino, dialkylamino, C1-6 alkenyl, C1-6 alkoxy, carboxylic acid, carboxylic ester, amide carboxylic, nitrile, sulfonamide, sulfamide, acyl sulfonamide, or R3 is an alkylaryl optionally substituted with one or more substituents selected independently from aryl, aryloxy, halogen, alkylamino, dialkylamino, C1-6 alkyl, C1-6 alkenyl C1-6 alkoxy, carboxylic acid, carboxylic ester, carboxylic amide, nitrile, sulfonamide, sulfamide, or acyl sulfonamide.
    [008] The compounds of formula (I) and their salts, tautomer (s), stereoisomeric forms, solvate or pharmaceutically acceptable polymorph have activity as pharmacists, in particular as modulators of Toll 7 and 8 type receptors (especially TLR 8).
    [009] In a further aspect, the present invention provides a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt, tautomer, stereoisomer, solvate or polymorph thereof together with one or more excipients, diluents or pharmaceutically carriers acceptable.
    [0010] Furthermore, a compound of the formula (I) or a pharmaceutically acceptable salt, solvate, tautomer, stereoisomeric form or polymorph thereof according to the present invention, or a pharmaceutical composition comprising said compound of the formula (I) or a salt, solvate, tautomer, stereoisomeric form or pharmaceutically acceptable polymorph of the same can be used as a medicine.
    [0011] Another aspect of the invention is that a compound of formula (1) or its salt, solvate, tautomer, stereoisomeric form or pharmaceutically acceptable polymorph, or said pharmaceutical composition comprising said compound of formula (I) or a salt, solvate , tautomer, stereoisomeric form or pharmaceutically acceptable polymorph thereof, can be used appropriately in the treatment of a disorder in which the modulation of TLR7 and / or TLR8 is involved, preferably TLR8.
    [0012] The terms "(C1-8) alkyl" and "(C1-6) alkyl" refer to a saturated straight chain, branched or cyclic aliphatic hydrocarbon containing the specified number of carbon atoms.
    [0013] The term "halogen" refers to fluorine, chlorine, bromine or iodine.
    [0014] The term "alkylaryl" refers to a saturated straight chain or branched chain aliphatic hydrocarbon containing the specified number of carbon atoms replaced with an aryl, where "aryl" is defined according to the definition below.
    [0015] The term "alkenyl" refers to an alkyl as defined above consisting of at least two carbon atoms and at least one carbon-carbon double bond.
    [0016] The term "cycloalkyl" refers to a carbocyclic ring containing the specified number of carbon atoms.
    [0017] The term "alkoxy" refers to an alkyl group (carbon and hydrogen chain) linked by means of a simple bond to oxygen, such as a methoxy group or an ethoxy group.
    [0018] The term "aryl" means an aromatic ring structure optionally comprising one or two heteroatoms selected from N, O and S, in particular N and O. Said aromatic ring structure can have 5, 6 or 7 atoms in ring. In particular, said aromatic ring structure can have 5 or 6 ring atoms.
    [0019] The term "aryloxy" refers to an aromatic ring structure. Said aromatic group is linked by simple bond to oxygen.
    [0020] As used herein, any chemical formula with bonds shown only as solid lines and not as solid minted or perforated minted bonds, or otherwise indicated as having a particular configuration (for example, R, S) around one or more atoms, contemplates each possible stereoisomer, or mixture of two or more stereoisomers.
    [0021] The terms "stereoisomers", "stereoisomeric forms" or "stereochemically isomeric forms" previously or hereinafter are used interchangeably.
    [0022] The invention includes all the stereoisomers of the compounds of the invention as a pure stereoisomer or as a mixture of two or more stereoisomers.
    [0023] Enantiomers are stereoisomers that are scattered images of one another not overlapping. A 1: 1 mixture of a pair of enantiomers is a racemate or racemic mixture.
    [0024] Diastereomers (or diastereoisomers) are stereoisomers that are not enantiomers, that is, they are not related as mirror images. If a compound contains a double bond, the substituents can be in the E or Z configuration. If a compound contains an at least disubstituted non-aromatic cyclic group, the substituents can be in the cis or trans configuration.
    [0025] Therefore, the invention includes enantiomers, diastereoisomers, racemates, E isomers, Z isomers, cis isomers, trans isomers and their mixtures, whenever it is chemically possible.
    [0026] The meaning of all these terms, that is, enantiomers, diastereoisomers, racemates, E isomers, Z isomers, cis isomers, trans isomers and their mixtures is known to the expert.
    [0027] The absolute configuration is specified according to the Cahn-Ingold-Prelog system. The configuration on an asymmetric atom is specified by R or S. The resolved stereoisomers whose absolute configuration is not known can be designated by (+) or (-) depending on the direction in which they rotate plane polarized light. For example, resolved enantiomers whose absolute configuration is not known can be called (+) or (-) depending on the direction in which they rotate plane polarized light.
    [0028] When a specific stereoisomer is identified, it means that said stereoisomer is substantially free, that is, associated with less than 50%, preferably less than 20%, more preferably less than 10%, even more preferably less than 5%, in particular less than 2% and most preferably less than 1%, of the other stereoisomers. Thus, when a compound of Formula (I) is, for example, specified as (R), this means that the compound is substantially free of the (S) isomer; when a compound of Formula (I) is, for example, specified as E, this means that the compound is substantially free of the Z isomer; when a compound of Formula (I) is, for example, specified as cis, this means that the compound is substantially free of the trans isomer.
    [0029] Pharmaceutically acceptable salts of the compounds of formula (I) include their acid and basic addition salts. Suitable acid addition salts are formed from acids that form non-toxic salts. Appropriate basic salts are formed from bases that form non-toxic salts.
    [0030] The compounds of the invention can also exist in solvated and unsolvated forms. The term "solvate" is used here to describe a molecular complex comprising the compound of the invention and one or more pharmaceutically acceptable solvent molecules, for example, ethanol.
    [0031] The term "polymorph" refers to the ability of the compound of the invention to exist in more than one crystalline form or structure.
    [0032] The compounds of the present invention can be administered as crystalline or amorphous products. They can be obtained, for example, as solid buffers, powders, or films, by methods such as precipitation, crystallization, lyophilization, spray drying, or evaporative drying. They can be administered alone or in combination with one or more other compounds of the invention, or in combination with one or more other drugs. Generally, they will be administered as a formulation in association with one or more pharmaceutically acceptable excipients. The term "excipient" is used here to describe any ingredient other than the compound (s) of the invention. The choice of excipient depends largely on factors such as the particular mode of administration, the effect of the excipient on solubility and stability, and the nature of the dosage form.
    The compounds of the present invention or any subgroup thereof can be formulated in various dosage forms for administration purposes. As appropriate compositions, all compositions usually used for systemic drug administration can be cited. To prepare the pharmaceutical compositions of this invention, an effective amount of the particular compound, optionally in the form of an addition salt, as the active ingredient is combined in admixture with a pharmaceutically acceptable carrier, the carrier being able to have a wide variety in ways depending on the form of preparation desired for administration. These pharmaceutical compositions are desirably in the form of unit dosages suitable, for example, for oral, rectal or percutaneous administration. For example, in the preparation of compositions in oral dosage form, any of the usual pharmaceutical means such as, for example, water, glycols, oils, alcohols and the like can be employed in the case of liquid oral preparations such as suspensions, syrups, elixirs , emulsions and solutions; or solid vehicles such as starches, sugars, kaolin, thinners, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Due to their ease of administration, tablets and capsules represent the most advantageous oral dosage unit forms, in which case solid pharmaceutical carriers are obviously employed. Also included are preparations in solid form that can be converted, immediately before use, into liquid forms. In compositions suitable for percutaneous administration, the vehicle optionally comprises a penetration enhancing agent and / or a suitable wetting agent, optionally combined with suitable additives of any nature in minimal proportions, with the additives having no significant deleterious effect on the skin. Said additives can facilitate administration to the skin and / or can be useful for preparing the desired compositions. These compositions can be administered in various ways, for example, as a transdermal patch, as an adhesive, as an ointment. The compounds of the present invention can also be administered by inhalation or insufflation using methods and formulations employed in the art for administration by this route. Thus, in general the compounds of the present invention can be administered to the lungs in the form of a solution, a suspension or a dry powder.
    [0034] It is especially advantageous to formulate the pharmaceutical compositions mentioned above in unit dosage form for ease of administration and uniformity of dosage. Unit dosage form, as used herein, refers to physically discrete units, suitable as unitary dosages, each unit containing a predetermined amount of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such unit dosage forms are tablets (including grooved or coated tablets), capsules, pills, powder packages, crackers, suppositories, suspensions or injectable solutions and the like, and their multiple secretions.
    [0035] Experts in the treatment of infectious diseases will be able to determine the effective amount from the test results presented hereinafter. In general it is contemplated that an effective daily amount would be 0.01 mg / kg to 50 mg / kg of body weight, more preferably 0.1 mg / kg to 10 mg / kg of body weight. It may be appropriate to administer the required dose as two, three, four or more sub-doses at appropriate intervals during the day. Said underdoses can be formulated as unit dosage forms, for example, containing 1 to 1000 mg, and in particular 5 to 200 mg of active ingredient per unit dosage form.
    [0036] The exact dosage and frequency of administration depend on the particular formula (I) compound used, the particular condition to be treated, the severity of the condition to be treated, the age, weight and general physical condition of the particular patient, as well as any other medication that the individual may be taking, as is well known to those skilled in the art. Furthermore, it is evident that the effective amount can be decreased or increased depending on the response of the treated subject and / or depending on the physician's judgment in prescribing the compounds of the present invention. The effective amount ranges mentioned above are therefore guidelines only and are not intended to limit the scope or use of the invention to any extent. Preparation of Compounds of Formula (I) General scheme.

    [0037] The preparation of type I compounds is described in the literature (Synthetic Communications, 9 (8), pp. 731-734, 1979; Synthetic Communications, 32 (16), 2565-2568; 2002). 3-Aminothiophene-2-carboxylates are mixed with cyanamide in a polar solvent (eg, ethanol) containing acid (eg, HCl) to form intermediates II with heat as described in the literature (Synthesis, (9), p1428, 2010). Intermediate II in polar aprotic solvent can be mixed with BOP or PyBOP in combination with a base (eg, DBU) and the amine to result in the formation of final products (III) at room temperature. Alternatively, alcohol in type II intermediates can be converted to chlorine using described methods and chlorinating agents, such as POCl3, often with heat and in the presence of solvent, and optionally with a base. After isolation, the 4-chlorine intermediate can then be used to form type III products by heating with the amine in a base and a polar solvent (for example, acetonitrile). Preparation of 1

    [0038] B (500 mg, 2.76 mmol), anhydrous DMF (5 mL), DBU (1.26 g, 8.28 mmol), n-butylamine ( 605 mg, 8.3 mmols), and BOP (1.46 g, 3.31 mmols). The flask was sealed and shaken for 16 hours at room temperature. LC-MS showed conversion to product. The crude reaction mixture was purified by preparative HPLC (RP SunFire Prep C18 OBD-10 μm, 30 x 150 mm, mobile phase 0.25% aq. Ammonium carbonate to acetonitrile). The best fractions were combined and the solvents removed under reduced pressure to provide a white solid, 1. LC-MS m / z = 237 (M + H).




    Analytical Methods
    [0039] General information: LC measurement was performed using an Acquity UPLC (Waters) system comprising a binary pump, a sample organizer, a column heater (set at 55 ° C), a diode array detector (DAD ) and a column as specified in the respective methods below. The column flow was separated for an MS spectrometer. The MS detector was configured with an electrospray ionization source. Mass spectra were acquired by screening from 100 to 1000 in 0.18 seconds using a dwell time of 0.02 seconds. The capillary needle voltage was 3.5 kV and the source temperature was maintained at 140 ° C. Nitrogen was used as the nebulizer gas.
    Biological Activity of Compounds of Formula (I) Description of Biological Assays Evaluation of TLR7 and TLR8 Activity
    [0040] The ability of compounds to activate human TLR7 and / or TLR8 was evaluated in a cell reporter assay using HEK293 cells transiently transfected with a TLR7 or TLR8 expression vector and an NFKB-IUC reporter construct.
    [0041] Briefly, HEK293 cells were cultured in culture medium (DMEM supplemented with 10% SFB and 2 mM Glutamine). For transfection of cells in 15 cm plates, cells were detached with Trypsin-EDTA, transfected with a mixture of plasmid CMV-TLR7 or TLR8 (1700 ng), plasmid NFKB-IUC (850 ng) and a transfection reagent and incubated for 48 h at 37 ° C in a humidified 5% CO2 atmosphere. The transfected cells were then washed in PBS, detached with Trypsin-EDTA and resuspended in medium to a density of 1.25 x 105 cells / ml. Forty microliters of cells were then dispensed into each well in 384-well plates, where 200 nL of 100% DMSO compound was already present. After incubation for 6 hours at 37 ° C, 5% CO2, luciferase activity was determined by adding 15 μL of Steady Lite Plus substrate (Perkin Elmer) to each well and reading on a ViewLux ultraHTS microplate imager ( Perkin Elmer). Dose response curves were generated from quadruplicate measurements. The values of the minimum effective concentrations (LEC), defined as the concentration that induces an effect that is at least twice the standard deviation of the test, were determined for each compound.
    [0042] The toxicity of the compounds was determined in parallel using a series of similar dilutions of compound with 40 μL per well of cells transfected with the CMV-TLR7 construct alone (1.25 x 105 cells / mL), in plates 384 wells. The viability of the cells was measured after incubation for 6 hours at 37 ° C, 5% CO2, by adding 15 μL of ATP lite (Perkin Elmer) per well and reading in a ViewLux ultraHTS microplate imager (Perkin Elmer). The data were reported as CC50.
    [0043] In parallel, a series of similar dilutions of compound was used (200 nL of compound in 100% DMSO) with 40 μL per well of cells transfected with only the NFKB-luc reporter construct (1.25 x 105 cells / mL). Six hours after incubation at 37 ° C, 5% CO2, luciferase activity was determined by adding 15 μL of Steady Lite Plus substrate (Perkin Elmer) to each well and reading on a ViewLux ultraHTS microplate imager (Perkin Elmer). Counter-tracking data is reported as LEC. Activation of ISRE Promoter Elements
    [0044] The potential of compounds to induce IFN-I was also assessed by measuring the activation of responsive elements stimulated by interferon (ISRE) using conditioned PBMC. The ISA element of the GAAACTGAAACT sequence is highly responsive to the transcription factor STAT1-STAT2-IRF9, activated after binding IFN-I to its IFNAR receptor (Clontech, PT3372-5W). Clontech's pISRE-Luc plasmid (ref. 631913) contains 5 copies of this ISRE element, followed by the ORF of the firefly luciferase. A HEK293 cell line stably transfected with pISRE-Luc (HEK-ISREluc) was established to characterize the conditioned culture medium of PBMC cells.
    [0045] Briefly, PBMCs were prepared from buffy coat layers from at least two donors using a standard Ficoll centrifugation protocol. Isolated PBMCs were resuspended in RPMI medium supplemented with 10% human AB serum and 2 x 105 cells / well were dispensed in 384-well plates containing compounds (total volume 70 μL). After overnight incubation, 10 μL of supernatant was transferred to 384-well plates containing 5 x 103 HEK-ISREluc cells / well in 30 μL (plated the previous day). After 24 hours of incubation, activation of the ISRE elements was measured by assessing luciferase activity using 40 μL / well of Steady Lite Plus substrate (Perkin Elmer) and measured with a ViewLux ultraHTS microplate imager (Perkin Elmer). The stimulatory activity of each compound in HEK-ISREluc cells was reported as an LEC value, defined as the concentration of compound applied to PBMCs resulting in a luciferase activity at least twice above the standard deviation of the assay. The LEC indicates, in turn, the degree of ISRE activation after transferring a defined amount of PBMC culture medium. Recombinant α-2a interferon (Roferon-A) was used as a standard control compound. Table 2. Biological activity of compounds of formula (I).

    All compounds showed no activity (LEC> 25 μM) in the HEK 293 NF-kB counter-screening assay described above.
    权利要求:
    Claims (6)
    [0001]
    1. Compound, characterized by the fact that it presents the formula (I)
    [0002]
    2. Compound according to claim 1, characterized by the fact that R1 and R2 are both hydrogen and in which R3 is C1-8alkyl substituted with hydroxyl.
    [0003]
    3. Compound according to claim 2, characterized by the fact that it has the structure
    [0004]
    4. Pharmaceutical composition, characterized in that it comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in claim 1, together with one or more pharmaceutically acceptable excipients, diluents or vehicles.
    [0005]
    A compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 1 or a pharmaceutical composition according to claim 4, characterized (a) in that it is for use as a medicament.
    [0006]
    6. Compound of formula (I), characterized by the fact that it is selected from the group consisting of:
    类似技术:
    公开号 | 公开日 | 专利标题
    BR112016001570B1|2020-12-15|TIENO DERIVATIVES [3,2-D] PYRIMIDINES AND PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS THEM FOR THE TREATMENT OF VIRAL INFECTIONS
    ES2733361T3|2019-11-28|2-Aminopyrimidine derivatives for the treatment of viral infections
    ES2707885T3|2019-04-05|Alkylpyrimidines for the treatment of viral infections and other diseases
    BR112015007586B1|2021-02-09|pyrrole [3,2-d] pyrimidine derivatives, their use and pharmaceutical composition comprising them
    ES2716811T3|2019-06-17|Piperidinopyrimidine derivatives for the treatment of viral infections
    BR112015011036B1|2022-02-01|Heterocyclic Substituted 2-Amino-quinazoline Derivatives, Pharmaceutical Composition
    KR102280559B1|2021-07-22|Pyridone derivatives for the treatment of viral infections and further diseases
    BR112014019699B1|2021-12-07|PIPERIDINO-PYRIMIDINE DERIVATIVES, THEIR USE IN THE TREATMENT OF VIRAL INFECTIONS AND THE PHARMACEUTICAL COMPOSITION THAT COMPRISES THEM
    BR112015002524B1|2021-11-03|ALKYLPYRIMIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITION INCLUDING THEM AND THE USE OF THE SAME
    同族专利:
    公开号 | 公开日
    IL242872A|2019-06-30|
    US20160168164A1|2016-06-16|
    EP3404031B1|2020-09-23|
    MX2016001464A|2016-06-02|
    KR102322425B1|2021-11-05|
    AU2014298540A1|2015-12-17|
    MX368625B|2019-10-08|
    CA2913691A1|2015-02-05|
    PH12015502797B1|2016-03-14|
    CA2913691C|2022-01-25|
    EA036162B1|2020-10-08|
    US9556199B2|2017-01-31|
    ES2836881T3|2021-06-28|
    ES2701239T3|2019-02-21|
    EP3027624B1|2018-09-12|
    US10822347B2|2020-11-03|
    AU2018256591B2|2020-03-19|
    HK1217707A1|2017-01-20|
    SG10201804306VA|2018-06-28|
    CN105492446A|2016-04-13|
    DK3404031T3|2020-12-14|
    WO2015014815A1|2015-02-05|
    MY179503A|2020-11-09|
    AU2014298540B2|2018-08-09|
    EP3027624A1|2016-06-08|
    NZ714519A|2021-07-30|
    CN108912137B|2021-04-09|
    UA117253C2|2018-07-10|
    IL266897D0|2019-07-31|
    CL2015003767A1|2016-07-08|
    SG11201510736PA|2016-02-26|
    EA201690303A1|2016-06-30|
    EP3404031A1|2018-11-21|
    DK3027624T3|2019-01-07|
    CN108912137A|2018-11-30|
    IL266897A|2020-11-30|
    US20170298079A1|2017-10-19|
    JP2016525148A|2016-08-22|
    PH12015502797A1|2016-03-14|
    US20190330227A1|2019-10-31|
    CN105492446B|2018-08-03|
    AU2018256591A1|2018-11-22|
    IL242872D0|2016-02-01|
    KR20160035583A|2016-03-31|
    JP6401788B2|2018-10-10|
    US10316043B2|2019-06-11|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    JP2610889B2|1987-09-03|1997-05-14|日本臓器製薬株式会社|New crosslinked adenine derivatives|
    JP4667543B2|1996-07-03|2011-04-13|大日本住友製薬株式会社|New purine derivatives|
    EA002769B1|1996-08-28|2002-08-29|Пфайзер Инк.|Substituted 6,5-hetero-bicyclic derivatives|
    DE69717867T2|1996-10-04|2003-10-02|Kyorin Seiyaku Kk|PYRAZOLOPYRIDYLPYRAZINONE DERIVATIVES AND A METHOD FOR THE PRODUCTION THEREOF|
    AR012634A1|1997-05-02|2000-11-08|Sugen Inc|QUINAZOLINE BASED COMPOUND, FAMACEUTICAL COMPOSITION THAT UNDERSTANDS IT, METHOD TO SYNTHESIZE IT, ITS USE, METHODS OF MODULATION OF THE DESERINE / TREONIN PROTEIN-KINASE FUNCTION AND IN VITRO METHOD TO IDENTIFY COMPOUNDS THAT MODULATE|
    US6339089B2|1997-08-13|2002-01-15|Fujirebio Inc.|Pyrimidine nucleus-containing compound and a medicament containing the same for a blood oxygen partial pressure amelioration, and a method for preparing the same|
    ES2205573T3|1997-11-28|2004-05-01|Sumitomo Pharmaceuticals Company, Limited|NEW HETEROCICLIC COMPOUNDS.|
    TW572758B|1997-12-22|2004-01-21|Sumitomo Pharma|Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives|
    US6187777B1|1998-02-06|2001-02-13|Amgen Inc.|Compounds and methods which modulate feeding behavior and related diseases|
    EP1056742B1|1998-02-17|2003-07-23|Tularik, Inc.|Anti-viral pyrimidine derivatives|
    US6110929A|1998-07-28|2000-08-29|3M Innovative Properties Company|Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof|
    JP4342007B2|1998-08-10|2009-10-14|大日本住友製薬株式会社|Quinazoline derivatives|
    JP4315300B2|1998-08-10|2009-08-19|大日本住友製薬株式会社|Novel quinazoline derivatives|
    WO2000012487A1|1998-08-27|2000-03-09|Sumitomo Pharmaceuticals Co., Ltd.|Pyrimidine derivatives|
    US6583148B1|1999-04-08|2003-06-24|Krenitsky Pharmaceuticals, Inc.|Neurotrophic substituted pyrimidines|
    US6503908B1|1999-10-11|2003-01-07|Pfizer Inc|Pharmaceutically active compounds|
    WO2002088079A2|2001-05-01|2002-11-07|Bristol-Myers Squibb Company|Dual inhibitors of pde 7 and pde 4|
    WO2003055890A1|2001-12-21|2003-07-10|Bayer Pharmaceuticals Corporation|Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents|
    TW200407143A|2002-05-21|2004-05-16|Squibb Bristol Myers Co|Pyrrolotriazinone compounds and their use to treat diseases|
    US7091232B2|2002-05-21|2006-08-15|Allergan, Inc.|4- imidazole-2-thiones, 4- imidazole-2-thiones, 4- imidazol-2-ones and 4- imidazol-2-ones and related compounds|
    WO2003104230A1|2002-06-07|2003-12-18|協和醱酵工業株式会社|Bicyclic pyrimidine derivatives|
    KR101111085B1|2002-09-27|2012-04-12|다이닛본 스미토모 세이야꾸 가부시끼가이샤|Novel adenine compound and use thereof|
    US8455458B2|2002-10-16|2013-06-04|Arthrodynamic Technologies, Animal Health Division, Inc.|Composition and method for treating connective tissue damage|
    MXPA05013922A|2003-06-20|2006-02-24|Coley Pharm Group Inc|Small molecule toll-like receptor antagonists.|
    WO2005025583A2|2003-09-05|2005-03-24|Anadys Pharmaceuticals, Inc.|Tlr7 ligands for the treatment of hepatitis c|
    EP1728792A4|2004-03-26|2010-12-15|Dainippon Sumitomo Pharma Co|8-oxoadenine compound|
    UA86798C2|2004-03-26|2009-05-25|ДАЙНИППОН СУМИТОМО ФАРМА Ко., ЛТД.|9-substituted 8-oxoadenine compound|
    WO2007084413A2|2004-07-14|2007-07-26|Ptc Therapeutics, Inc.|Methods for treating hepatitis c|
    CA2575002C|2004-08-10|2015-01-20|Janssen Pharmaceutica N.V.|Hiv inhibiting 1,2,4-triazin-6-one derivatives|
    AU2005304040B2|2004-11-09|2009-04-23|F. Hoffmann-La Roche Ag|Aminoquinazolines compounds|
    US7498409B2|2005-03-24|2009-03-03|Schering Corporation|Screening assay for TLR7, TLR8 and TLR9 agonists and antagonists|
    BRPI0611435A2|2005-05-04|2010-09-08|Pfizer Ltd|2-starch-6-amino-8-oxopurine derivatives, pharmaceutical compositions, use and process for preparing same|
    AR054122A1|2005-05-12|2007-06-06|Tibotec Pharm Ltd|PIRIDO [2,3-D] USEFUL PYRIMIDES AS HCV INHIBITORS, AND METHODS FOR THE PREPARATION OF THE SAME|
    US7994360B2|2005-05-16|2011-08-09|Xtl Biopharmaceuticals Ltd.|Benzofuran compounds|
    EP1924564B1|2005-09-01|2016-11-09|F.Hoffmann-La Roche Ag|Diaminopyrimidines as p2x3 and p2x2/3 modulators|
    US20090192153A1|2005-09-22|2009-07-30|Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan|Novel adenine compound|
    WO2007056208A2|2005-11-02|2007-05-18|Cytovia, Inc.|N-arylalkyl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof|
    WO2007063934A1|2005-12-02|2007-06-07|Mitsubishi Tanabe Pharma Corporation|Alicyclic heterocyclic compound|
    KR20080085232A|2006-02-17|2008-09-23|화이자 리미티드|3-deazapurine derivatives as tlr7 modulators|
    WO2008009077A2|2006-07-20|2008-01-24|Gilead Sciences, Inc.|4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections|
    WO2008009078A2|2006-07-20|2008-01-24|Gilead Sciences, Inc.|4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections|
    ZA200904531B|2006-12-07|2010-09-29|Hoffmann La Roche|Phosphoinositide 3-kinase inhibitor compounds and methods of use|
    CA2672250C|2006-12-20|2013-04-30|Ian Stansfield|Antiviral indoles|
    HUE025555T2|2007-02-07|2016-02-29|Univ California|Conjugates of synthetic tlr agonists and uses therefor|
    JP2008222557A|2007-03-08|2008-09-25|Kotobuki Seiyaku Kk|PYRROLO[3,2-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS EFFECTIVE COMPONENT|
    PT2132209E|2007-03-19|2014-04-15|Astrazeneca Ab|9-substituted-8-oxo-adenine compounds as toll-like receptor modulators|
    AR065784A1|2007-03-20|2009-07-01|Dainippon Sumitomo Pharma Co|DERIVATIVES OF 8-OXO ADENINE, DRUGS THAT CONTAIN THEM AND USES AS THERAPEUTIC AGENTS FOR ALLERGIC, ANTIVIRAL OR ANTIBACTERIAL DISEASES.|
    EP2138497A4|2007-03-20|2012-01-04|Dainippon Sumitomo Pharma Co|Novel adenine compound|
    WO2008147697A1|2007-05-22|2008-12-04|Boehringer Ingelheim International Gmbh|Benzimidazolone chymase inhibitors|
    EA024359B1|2007-06-29|2016-09-30|Джилид Сайэнс, Инк.|Purine derivatives and their use as modulators of toll-like receptor 7|
    AU2008287421A1|2007-08-10|2009-02-19|Glaxosmithkline Llc|Nitrogen containing bicyclic chemical entities for treating viral infections|
    JP2010538004A|2007-08-28|2010-12-09|アイアールエム・リミテッド・ライアビリティ・カンパニー|2-Biphenylamino-4-aminopyrimidine derivatives as kinase inhibitors|
    WO2009030998A1|2007-09-05|2009-03-12|Coley Pharmaceutical Group, Inc.|Pyrimidine compounds as toll-like receptor agonists|
    PE20091236A1|2007-11-22|2009-09-16|Astrazeneca Ab|PYRIMIDINE DERIVATIVES AS IMMUNOMODULATORS OF TLR7|
    DK2238142T3|2007-12-24|2012-10-08|Janssen R & D Ireland|Macrocyclic indoles such as hepatitis C virus inhibitors|
    WO2009099650A2|2008-02-07|2009-08-13|Carson Dennis A|Treatment of bladder diseases with a tlr7 activator|
    SI2268618T1|2008-03-03|2015-09-30|Novartis Ag|Compounds and compositions as tlr activity modulators|
    US8461107B2|2008-04-28|2013-06-11|Merck Sharp & Dohme Corp.|HCV NS3 protease inhibitors|
    US8946239B2|2008-07-10|2015-02-03|Duquesne University Of The Holy Spirit|Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof|
    UY31982A|2008-07-16|2010-02-26|Boehringer Ingelheim Int|DERIVATIVES OF 1,2-DIHYDROPIRIDIN-3-CARBOXAMIDS N-SUBSTITUTED|
    EA201101650A1|2009-05-21|2012-07-30|Астразенека Аб|NEW PYRIMIDINE DERIVATIVES AND THEIR APPLICATION IN THE TREATMENT OF MALIGNANT NONFORMS AND THE FOLLOWING DISEASES|
    US8637525B2|2009-07-31|2014-01-28|Bristol-Myers Squibb Company|Compounds for the reduction of beta-amyloid production|
    TWI468402B|2009-07-31|2015-01-11|Squibb Bristol Myers Co|Compounds for the reduction of β-amyloid production|
    EP2491033A4|2009-10-20|2013-03-13|Eiger Biopharmaceuticals Inc|Azaindazoles to treat flaviviridae virus infection|
    SG10201406813RA|2009-10-22|2014-11-27|Gilead Sciences Inc|Derivatives of purine or deazapurine useful for the treatment of viral infections|
    KR101094446B1|2009-11-19|2011-12-15|한국과학기술연구원|2,4,7-Substituted thieno[3,2-d]pyrimidine compounds as protein kinase inhibitors|
    JP2013032290A|2009-11-20|2013-02-14|Dainippon Sumitomo Pharma Co Ltd|Novel fused pyrimidine derivative|
    DE102010040233A1|2010-09-03|2012-03-08|Bayer Schering Pharma Aktiengesellschaft|Bicyclic aza heterocycles and their use|
    WO2012066335A1|2010-11-19|2012-05-24|Astrazeneca Ab|Phenol compounds als toll -like receptor 7 agonists|
    WO2012067269A1|2010-11-19|2012-05-24|Dainippon Sumitomo Pharma Co., Ltd.|Aminoalkoxyphenyl compounds and their use in the treatment of disease|
    PE20140964A1|2011-03-30|2014-08-17|Boehringer Ingelheim Int|ANTICOAGULANT ANTIDOTES|
    HUE055286T2|2011-04-08|2021-11-29|Janssen Sciences Ireland Unlimited Co|Pyrimidine derivatives for the treatment of viral infections|
    CA2835229C|2011-05-18|2020-05-05|Janssen R&D Ireland|Quinazoline derivatives for the treatment of viral infections and further diseases|
    DK2776439T3|2011-11-09|2018-10-22|Janssen Sciences Ireland Uc|PURINE DERIVATIVES FOR TREATING VIRUS INFECTIONS|
    IN2014MN01736A|2012-02-08|2015-07-10|Janssen R & D Ireland|
    RS61664B1|2012-04-24|2021-04-29|Vertex Pharma|Dna-pk inhibitors|
    SI2872515T1|2012-07-13|2016-10-28|Janssen Sciences Ireland Uc|Macrocyclic purines for the treatment of viral infections|
    SG11201500814UA|2012-08-10|2015-03-30|Janssen Sciences Ireland Uc|Alkylpyrimidine derivatives for the treatment of viral infections and further diseases|
    EP2712866A1|2012-10-01|2014-04-02|Centre National de la Recherche Scientifique |1,2,4-triazine derivatives for the treatment of viral infections|
    EA034650B1|2012-10-05|2020-03-03|Янссен Сайенсиз Айрлэнд Юси|Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases|
    LT2906563T|2012-10-10|2018-06-11|Janssen Sciences Ireland Uc|Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases|
    US9663474B2|2012-11-16|2017-05-30|Janssen Sciences Ireland Uc|Heterocyclic substituted 2-amino quinazoline derivatives for the treatment of viral infections|
    CN105189468B|2013-02-21|2018-10-30|爱尔兰詹森科学公司|2- aminopyridine derivatives for treating viral infection|
    AU2014242954B2|2013-03-29|2018-03-15|Janssen Sciences Ireland Uc|Macrocyclic deaza-purinones for the treatment of viral infections|
    NZ714519A|2013-07-30|2021-07-30|Janssen Sciences Ireland Uc|Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections|
    WO2016007966A2|2014-07-11|2016-01-14|Northwestern University|2-imidazolyl-pyrimidine scaffolds as potent and selective inhibitors of neuronal nitric oxide synthase|HUE055286T2|2011-04-08|2021-11-29|Janssen Sciences Ireland Unlimited Co|Pyrimidine derivatives for the treatment of viral infections|
    DK2776439T3|2011-11-09|2018-10-22|Janssen Sciences Ireland Uc|PURINE DERIVATIVES FOR TREATING VIRUS INFECTIONS|
    SI2872515T1|2012-07-13|2016-10-28|Janssen Sciences Ireland Uc|Macrocyclic purines for the treatment of viral infections|
    LT2906563T|2012-10-10|2018-06-11|Janssen Sciences Ireland Uc|Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases|
    US9663474B2|2012-11-16|2017-05-30|Janssen Sciences Ireland Uc|Heterocyclic substituted 2-amino quinazoline derivatives for the treatment of viral infections|
    CN105189468B|2013-02-21|2018-10-30|爱尔兰詹森科学公司|2- aminopyridine derivatives for treating viral infection|
    AU2014242954B2|2013-03-29|2018-03-15|Janssen Sciences Ireland Uc|Macrocyclic deaza-purinones for the treatment of viral infections|
    SG11201509520QA|2013-05-24|2015-12-30|Janssen Sciences Ireland Uc|Pyridone derivatives for the treatment of viral infections and further diseases|
    UA117590C2|2013-06-27|2018-08-27|ЯНССЕН САЙЄНСЕЗ АЙРЛЕНД ЮСі|Solar protection glazing|
    NZ714519A|2013-07-30|2021-07-30|Janssen Sciences Ireland Uc|Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections|
    SG11201606876RA|2015-03-04|2016-10-28|Gilead Sciences Inc|Toll like receptor modulator compounds|
    JP2019524662A|2016-07-01|2019-09-05|ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー|Dihydropyranopyrimidines for the treatment of viral infections|
    EP3507288B1|2016-09-02|2020-08-26|Gilead Sciences, Inc.|4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators|
    US10370342B2|2016-09-02|2019-08-06|Gilead Sciences, Inc.|Toll like receptor modulator compounds|
    CN109790154A|2016-09-29|2019-05-21|爱尔兰詹森科学公司|For treating the pyrimidine prodrug of virus infection and other disease|
    SG10201914029RA|2016-10-14|2020-03-30|Precision Biosciences Inc|Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome|
    WO2019084060A1|2017-10-24|2019-05-02|Silverback Therapeutics, Inc.|Conjugates and methods of use thereof for selective delivery of immune-modulatory agents|
    CN111601822A|2017-12-15|2020-08-28|希沃尔拜克治疗公司|Antibody construct-drug conjugates for the treatment of hepatitis|
    US10966999B2|2017-12-20|2021-04-06|Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I.|3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein|
    US11203610B2|2017-12-20|2021-12-21|Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I.|2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein|
    KR20200124716A|2018-02-26|2020-11-03|길리애드 사이언시즈, 인코포레이티드|Substituted pyrrolysine compounds as inhibitors of HBV replication|
    EP3774883A1|2018-04-05|2021-02-17|Gilead Sciences, Inc.|Antibodies and fragments thereof that bind hepatitis b virus protein x|
    TW202010503A|2018-04-06|2020-03-16|捷克科學院有機化學與生物化學研究所|3’3’－cyclic dinucleotides|
    TW202005654A|2018-04-06|2020-02-01|捷克科學院有機化學與生物化學研究所|2'2'-cyclic dinucleotides|
    TW202005655A|2018-04-06|2020-02-01|捷克科學院有機化學與生物化學研究所|2'3'-cyclic dinucleotides|
    TW201945388A|2018-04-12|2019-12-01|美商精密生物科學公司|Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis B virus genome|
    TW202014193A|2018-05-03|2020-04-16|捷克科學院有機化學與生物化學研究所|2’3’-cyclic dinucleotides comprising carbocyclic nucleotide|
    WO2020028097A1|2018-08-01|2020-02-06|Gilead Sciences, Inc.|Solid forms of -11--12--3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid|
    JP2022500414A|2018-09-12|2022-01-04|シルバーバック セラピューティックス インコーポレイテッド|Methods and Compositions for Treating Diseases with Immunostimulatory Conjugates|
    CR20210215A|2018-10-31|2021-06-17|Gilead Sciences Inc|Substituted 6-azabenzimidazole compounds as hpk1 inhibitors|
    EP3873608A1|2018-10-31|2021-09-08|Gilead Sciences, Inc.|Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity|
    WO2020162705A1|2019-02-08|2020-08-13|성균관대학교산학협력단|Toll-like receptor 7 or 8 agonist-cholesterol complex, and use of same|
    WO2020178768A1|2019-03-07|2020-09-10|Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I.|3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator|
    WO2020178770A1|2019-03-07|2020-09-10|Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I.|3'3'-cyclic dinucleotides and prodrugs thereof|
    WO2020178769A1|2019-03-07|2020-09-10|Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I.|2'3'-cyclic dinucleotides and prodrugs thereof|
    EP3956329A1|2019-04-17|2022-02-23|Gilead Sciences, Inc.|Solid forms of a toll-like receptor modulator|
    WO2020214663A1|2019-04-17|2020-10-22|Gilead Sciences, Inc.|Solid forms of a toll-like receptor modulator|
    WO2020237025A1|2019-05-23|2020-11-26|Gilead Sciences, Inc.|Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors|
    AU2020298222A1|2019-06-19|2022-01-20|Silverback Therapeutics, Inc.|Anti-mesothelin antibodies and immunoconjugates thereof|
    WO2021034804A1|2019-08-19|2021-02-25|Gilead Sciences, Inc.|Pharmaceutical formulations of tenofovir alafenamide|
    WO2021067181A1|2019-09-30|2021-04-08|Gilead Sciences, Inc.|Hbv vaccines and methods treating hbv|
    WO2021067644A1|2019-10-01|2021-04-08|Silverback Therapeutics, Inc.|Combination therapy with immune stimulatory conjugates|
    WO2021113765A1|2019-12-06|2021-06-10|Precision Biosciences, Inc.|Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome|
    US11179473B2|2020-02-21|2021-11-23|Silverback Therapeutics, Inc.|Nectin-4 antibody conjugates and uses thereof|
    WO2021188959A1|2020-03-20|2021-09-23|Gilead Sciences, Inc.|Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same|
    WO2022006327A1|2020-07-01|2022-01-06|Silverback Therapeutics, Inc.|Anti-asgr1 antibody conjugates and uses thereof|
    法律状态:
    2018-01-23| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|
    2019-10-15| B07E| Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]|
    2019-11-19| B06U| Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]|
    2020-04-22| B06A| Patent application procedure suspended [chapter 6.1 patent gazette]|
    2020-08-25| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|
    2020-12-15| B16A| Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/07/2014, OBSERVADAS AS CONDICOES LEGAIS. |
    优先权:
    申请号 | 申请日 | 专利标题
    EP13178534.7|2013-07-30|
    EP13178534|2013-07-30|
    PCT/EP2014/066219|WO2015014815A1|2013-07-30|2014-07-29|THIENO[3,2-d]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS|
    [返回顶部]